![]() On January 26, 2023, the FDA will hold a meeting of its Vaccines and Related Biological Products Advisory Committee ( VRBPAC) to consider whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified and how and whether the composition and schedule for booster doses should be adjusted moving forward.įDA Authorizes Updated (Bivalent) COVID-19 Vaccines for Children Down to 6 Months of Age ![]() Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) continue to diligently monitor a variety of data sources to identify any potential risks of the vaccines and to ensure that information is available to the public.įDA to Hold Advisory Committee Meeting to Discuss Future Vaccination Regimens Addressing COVID-19 Yesterday, the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) was revised to include a Warning conveying that reports of adverse events following use of the vaccine under emergency use authorization suggest increased risks of myocarditis and pericarditis, particularly within the period 0 through 7 days following vaccination.ĬDC-FDA Letter to Florida Department of Health Regarding COVID-19 Vaccine Safety The FDA amended the emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent to provide for a single booster dose in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine. ![]() ![]() FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |